We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breast Milk DNA Test Investigated for Early Breast Cancer Detection

By LabMedica International staff writers
Posted on 07 Oct 2026

Breast cancer that develops during pregnancy or shortly after childbirth is often diagnosed late, after the disease has already spread. More...

Pregnancy-related breast cancer occurs in approximately one in 3,000 pregnancies in the general population, but among women at very high risk, such as BRCA gene carriers, rates have been reported as high as one in 50 pregnancies.

In the U.K., breast cancer is the leading cause of cancer-related death among women ages 35–64 and is rising faster in women under 50 than in older age groups. Between 35% and 50% of breast cancer cases in women under 55 occur within 10 years of having a baby, while 5% of cases in women under 45 occur within a year of giving birth, underscoring the need for improved screening, particularly in younger women.

Against this backdrop, researchers are investigating whether breast milk could provide an earlier signal of breast cancer than blood testing or imaging. Researchers at the University of Manchester are leading BRACELET-BM, a study evaluating breast milk as a potential noninvasive biofluid for breast cancer detection. The approach focuses on identifying cancer-related DNA fragments shed by cells into breast milk, with researchers comparing breast milk and blood samples to determine how each can be collected, processed, stored, and analyzed for biomarker testing.

The study has begun recruiting participants at the Nightingale Centre in Wythenshawe, part of Manchester University NHS Foundation Trust. Initial enrollment will include 40 lactating women, comprising 25 at general population risk and 15 at higher risk because of a family history of breast cancer. Samples will also be collected at Saint Mary’s Hospital, part of the same trust, to support development of the Manchester Breast Biofluid Biobank, which is expected to contain more than 200 samples for future research.

Fluid samples will be analyzed by the Cancer Research UK (CRUK) National Biomarker Centre at the University of Manchester. The work builds on an international study published in September 2023 showing that circulating tumor DNA could be detected in breast milk, although optimal methods for sample collection, processing, and storage have not yet been established. Participants will also complete questionnaires and interviews to assess whether the approach would be acceptable and practical if developed for broader use.

“Scientists in our laboratories have identified tiny fragments of genetic material shed by cells in some samples of breast milk that have been donated for this study. The DNA structure is unique in breast milk, and we now understand what this DNA looks like, which is a major step forward,” said Dr. Florent Mouliere, who leads a research team at the CRUK National Biomarker Centre in Manchester.

“We now need to focus on the main aim of this study, which is to explore how best to collect the samples, work out if they can be safely frozen in a home freezer (which would be a convenient method for a nursing mom), what time of day is best for a sample to be collected, and if other factors such as an infection in the mother or baby would affect the sample results,” added Dr. Mouliere.

Related Links
CRUK National Biomarker Centre
University of Manchester


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Slide Scanner System
NanoZoomer S540MD
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.